ArticleStem cell research & therapy2025
Immortalized human hair follicle-derived mesenchymal-like stromal cells for the long-term production of scalable Immunomodulatory and regenerative secretome.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization, Preconditioning, Safety, and Other Issues of MSC-Derived EVs and Secretome.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMesenchymal stromal cells (MSCs) exert therapeutic effects primarily through their secretome, rich in bioactive factors with immunomodulatory and regenerative properties. However, clinical application of MSC-derived secretome is hindered by donor variability, limited expansion, and replicative senescence. To address these issues, we developed immortalized human hair follicle-derived mesenchymal-like stromal cells (iHF-MSCs) as a consistent and scalable source of therapeutic secretome.
methodsHF-MSCs were isolated using a minimally invasive procedure and immortalized with lentiviral SV40 large T antigen. From 576 single-cell clones, C18 and C26 were selected based on proliferation capacity, absence of senescence, and retention of a mesenchymal-like phenotype. Characterization included RT-PCR, flow cytometry for surface markers, trilineage differentiation, and CD56 expression analysis. For immunomodulatory evaluation, cells were licensed with IFN-γ and TNF-α, and the resulting conditioned media (licensed CM) were analyzed by ELISA and cytokine arrays. PBMC proliferation and Treg induction were assessed using licensed CM, while unlicensed CM was tested for its regenerative effects on dermal and epidermal cell functions, including wound repair, tube formation assay as an indicator of angiogenic potential, and oxidative stress response.
resultsThe selected clones (C18 and C26) exhibited long-term stability, rapid expansion, and preserved mesenchymal-like phenotype and multipotency. Secretome profiling revealed an enriched composition of immunoregulatory (e.g., Gal-9, IL-1Ra, TSG-6) and pro-regenerative (e.g., VEGF, PDGF-AA, EGF) factors, with enhanced responsiveness to inflammatory licensing. Notably, iHF-MSCs maintained low immunogenicity and demonstrated superior functional performance: inhibition of PBMC proliferation, Treg induction, and promotion of skin cell proliferation, migration, tube formation, and oxidative stress protection.
conclusionThese results position iHF-MSCs as a robust and scalable platform for consistent production of therapeutic secretome, paving the way for innovative, cell-free immunomodulatory and regenerative therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.